JP2015205922A5 - - Google Patents

Download PDF

Info

Publication number
JP2015205922A5
JP2015205922A5 JP2015149921A JP2015149921A JP2015205922A5 JP 2015205922 A5 JP2015205922 A5 JP 2015205922A5 JP 2015149921 A JP2015149921 A JP 2015149921A JP 2015149921 A JP2015149921 A JP 2015149921A JP 2015205922 A5 JP2015205922 A5 JP 2015205922A5
Authority
JP
Japan
Prior art keywords
composition
controlled release
weight
composition according
release component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015149921A
Other languages
English (en)
Japanese (ja)
Other versions
JP5985719B2 (ja
JP2015205922A (ja
Filing date
Publication date
Priority claimed from GB0905567A external-priority patent/GB2460915B/en
Application filed filed Critical
Publication of JP2015205922A publication Critical patent/JP2015205922A/ja
Publication of JP2015205922A5 publication Critical patent/JP2015205922A5/ja
Application granted granted Critical
Publication of JP5985719B2 publication Critical patent/JP5985719B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015149921A 2008-06-16 2015-07-29 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法 Expired - Fee Related JP5985719B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13242908P 2008-06-16 2008-06-16
US61/132,429 2008-06-16
US20905609P 2009-03-02 2009-03-02
US61/209,056 2009-03-02
GB0905567A GB2460915B (en) 2008-06-16 2009-03-31 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
GB0905567.4 2009-03-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011514610A Division JP5788315B2 (ja) 2008-06-16 2009-06-16 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152977A Division JP2016199584A (ja) 2008-06-16 2016-08-03 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法

Publications (3)

Publication Number Publication Date
JP2015205922A JP2015205922A (ja) 2015-11-19
JP2015205922A5 true JP2015205922A5 (enExample) 2016-05-19
JP5985719B2 JP5985719B2 (ja) 2016-09-06

Family

ID=40672056

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011514610A Expired - Fee Related JP5788315B2 (ja) 2008-06-16 2009-06-16 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法
JP2015149921A Expired - Fee Related JP5985719B2 (ja) 2008-06-16 2015-07-29 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法
JP2016152977A Pending JP2016199584A (ja) 2008-06-16 2016-08-03 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011514610A Expired - Fee Related JP5788315B2 (ja) 2008-06-16 2009-06-16 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016152977A Pending JP2016199584A (ja) 2008-06-16 2016-08-03 血小板の循環レベルを減少させる薬剤の制御放出組成物およびそのための方法

Country Status (8)

Country Link
US (5) US20090324710A1 (enExample)
EP (1) EP2306985A2 (enExample)
JP (3) JP5788315B2 (enExample)
CN (1) CN102123699A (enExample)
CA (1) CA2728213A1 (enExample)
GB (2) GB2460915B (enExample)
IL (1) IL209977A0 (enExample)
WO (1) WO2010005480A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
EP2049123B2 (en) 2006-08-03 2016-08-24 Horizon Pharma AG Delayed-release glucocorticoid treatment of rheumatoid disease
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US20100034959A1 (en) * 2008-08-07 2010-02-11 Vector Corporation High solids, high molecular weight polymer coating
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 HMG?CoA 환원효소 억제제를 포함하는 복합제제
WO2011100263A1 (en) * 2010-02-10 2011-08-18 Exploramed Iii, Inc. Methods, systems and devices for treatment of cerebrospinal venous insufficiency and multiple sclerosis
JP5836357B2 (ja) * 2010-03-25 2015-12-24 エイオーピー オーファン ファーマスーティカルズ アクチエンゲゼルシャフトAOP Orphan Pharmaceuticals Aktiengesellschaft 本態性血小板血症を治療するための新規組成物
WO2012015825A2 (en) 2010-07-27 2012-02-02 Incept, Llc Methods and apparatus for treating neurovascular venous outflow obstruction
TR201007508A1 (tr) * 2010-09-14 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan bileşimler
EP2481411A1 (en) * 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
CN103329311A (zh) * 2011-10-13 2013-09-25 特种东海制纸株式会社 用于电化学元件的隔离物及其制造方法
CA2823168A1 (en) 2011-10-13 2013-04-18 Tokushu Tokai Paper Co., Ltd. Porous membrane and process for preparing the same
WO2013054884A1 (ja) * 2011-10-13 2013-04-18 特種東海製紙株式会社 微多孔膜及びその製造方法
RU2013134483A (ru) * 2011-10-13 2015-01-27 Токусю Токай Пейпер Ко., Лтд. Пористая мембрана и способ ее получения
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
CA2857430C (en) 2011-12-14 2019-12-03 Lts Lohmann Therapie-Systeme Ag Wafer and capsule formulations with enhanced dissolution rates for fenofibrate
CN103211785B (zh) * 2012-01-18 2017-06-27 北京天衡药物研究院有限公司 阿昔莫司膜控缓释微丸胶囊
ES2549106T3 (es) * 2014-03-07 2021-12-21 Galenicum Health S L U Composiciones farmacéuticas que comprenden anagrelida
DK3131549T3 (en) 2014-07-09 2018-05-28 Pf Medicament PROCEDURE FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL
US10022377B2 (en) * 2015-12-02 2018-07-17 Cipla Limited Method of treating hypertension
CN113588501B (zh) * 2015-12-08 2024-12-17 生物马特里卡公司 降低红细胞沉降速率
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
MX2020009132A (es) * 2018-03-02 2020-12-11 Novaliq Gmbh Composiciones farmaceuticas que comprenden nebivolol.
US12496311B2 (en) 2018-07-17 2025-12-16 Aronora, Inc. Methods for safely reducing thrombopoietin
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
CN109806250B (zh) * 2019-01-23 2021-09-24 吉林大学 一种含羟基脲的药物组合物的应用
CN114302712B (zh) * 2019-09-04 2023-08-04 鲁南贝特制药有限公司 一种阿昔莫司多单元缓释微丸片及其制备方法
EP4117638A1 (en) * 2020-03-09 2023-01-18 Sushma Paul BERLIA Controlled release formulations comprising drotaverine or salt thereof
US20230158004A1 (en) * 2020-04-22 2023-05-25 Yungjin Pharm. Co., Ltd. Enteric-coated preparation comprising pirfenidone having improved safety and stability, and method for preparing same
CN112089883B (zh) * 2020-09-14 2022-01-04 海南希睿达生物技术有限公司 一种医用冷敷敷料及其制备方法
CA3209336A1 (en) * 2021-03-09 2022-09-15 Lynn Kirkpatrick Modified release compositions of nafamostat and methods of using same

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31617A (en) * 1861-03-05 photo-uthcqfupheh
US587224A (en) * 1894-10-10 1897-07-27 Stewart Dixon Mckelvey Head-rest pad
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3427378A (en) * 1965-02-12 1969-02-11 American Cyanamid Co Sustained release encapsulated formula
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
US3555151A (en) * 1966-12-21 1971-01-12 Richardson Merrell Inc Long acting solid antacid
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3574820A (en) * 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
JPS5512411B2 (enExample) * 1974-03-12 1980-04-02
US4105776A (en) * 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4123403A (en) * 1977-06-27 1978-10-31 The Dow Chemical Company Continuous process for preparing aqueous polymer microsuspensions
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4258030A (en) * 1979-03-07 1981-03-24 Zeria-Shinyaku Kogyo Kabushiki Kaisha Urokinase preparation for oral administration
US4248857A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4444777A (en) 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4410520A (en) * 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) * 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4614517A (en) * 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4502888A (en) * 1982-12-13 1985-03-05 The Dow Chemical Company Aqueous dispersions of plasticized polymer particles
JPS6092299A (ja) * 1983-10-25 1985-05-23 Sanwa Kosan Kk 粉末マルト−スの製造法
US4568676A (en) 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
DE3447669A1 (de) * 1983-12-29 1985-07-18 Hitachi, Ltd., Tokio/Tokyo Verbundstruktur aus metall und kunstharz sowie verfahren zu deren herstellung
US4780401A (en) 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US4851345A (en) * 1985-01-14 1989-07-25 Terumo Kabushiki Kaisha Fibrinophilic urokinase complex and method for production thereof
IT1191674B (it) * 1986-03-07 1988-03-23 Eurand Spa Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale
US4816463A (en) * 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5098840A (en) * 1986-07-03 1992-03-24 The Green Cross Corporation Human prourokinase mutants
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) * 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US5052558A (en) * 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5081127A (en) * 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5185323A (en) * 1988-03-31 1993-02-09 Temple University Suppression of megakaryocytopoiesis employing platelet factor 4 antimaturation factor
JPH0788352B2 (ja) * 1988-06-16 1995-09-27 エスエス製薬株式会社 ヒドロキシアルキルシステイン誘導体およびこれを含有する去痰剤
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5686569A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5085992A (en) * 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
WO1993009794A1 (en) * 1991-11-15 1993-05-27 University Of Pennsylvania Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
US5323907A (en) * 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
SE9301057L (sv) * 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5342626A (en) * 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SG43841A1 (en) 1994-01-10 1997-11-14 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ES2139959T3 (es) * 1994-10-27 2000-02-16 Merck Frosst Canada Inc Derivados de estilbeno utiles como inhibidores de la ciclooxigenasa-2.
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US7070972B1 (en) * 1995-01-13 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Janus family kinases and identification of immune modulators
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
SE9502244D0 (sv) * 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
JP3693270B2 (ja) 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
EP0792647A1 (en) 1996-02-27 1997-09-03 Roche Diagnostics GmbH Porphyrins as urokinase-type plasminogen activator receptor antagonists
US5798246A (en) * 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
GB9607503D0 (en) * 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6451609B1 (en) 1996-05-30 2002-09-17 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2265827A1 (en) 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
DE69822307T2 (de) 1997-06-03 2005-02-17 Kureha Chemical Industry Co., Ltd. Menschliches adamts-1 protein, gen , welches für dieses kodiert, pharmazeutische zusammensetzung und verfahrem zur immunologischen bestimmung von menschlichen adamts-1 proteinen
ATE308535T1 (de) * 1997-07-31 2005-11-15 Hoffmann La Roche O-substituierte hydroxycumaranonderivate mit antitumoraler und antimetastatischer wirkung
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4805461B2 (ja) * 1999-03-18 2011-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 血小板接着の阻止用タンパク質
JP3849428B2 (ja) * 1999-04-23 2006-11-22 日本新薬株式会社 微粉化法
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
DE10006286C1 (de) * 2000-02-14 2001-10-18 3M Espe Ag Lichtwellenkonvertervorrichtung und deren Verwendung im Dentalbereich
JP5102423B2 (ja) * 2000-04-20 2012-12-19 オバン・エナジー・リミテッド 改善された水不溶性薬剤粒子の処理
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
GB2364714A (en) 2000-07-17 2002-02-06 British Sugar Plc Spray-drying a material in the presence of a particulate solid
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
AU2002212145A1 (en) * 2000-08-23 2002-03-04 Wilex Ag Urokinase peptide structure mimetics
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100481444B1 (ko) * 2002-03-18 2005-04-11 원 호 이 에너지 절약형 조도 조절기
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
DE60326709D1 (de) * 2002-04-29 2009-04-30 Supernus Pharmaceuticals Inc Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
US6735009B2 (en) 2002-07-16 2004-05-11 Motorola, Inc. Electroptic device
JP4133109B2 (ja) * 2002-08-20 2008-08-13 新キャタピラー三菱株式会社 建設機械におけるシャッター式のガード装置
US7241411B2 (en) * 2002-08-23 2007-07-10 Acupac Packaging, Inc. Thin film strips
DE60238283D1 (de) * 2002-11-25 2010-12-23 Jallal Messadek Betain und Salicylsäure Zusammensetzungen
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
WO2005111083A2 (en) * 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Jak­2 조절자로서 4­아릴­2­아미노­피리미딘 또는 4­아릴­2­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
KR100870396B1 (ko) * 2006-12-07 2008-11-25 보령제약 주식회사 심혈관계 질환 치료용 경구투여제제
BRPI0807807A2 (pt) * 2007-01-25 2014-06-17 Panacea Biotec Ltd " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ".
CN101984745B (zh) 2007-09-07 2013-08-14 Qlt股份有限公司 用于持续释放治疗药物的药物核心
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor

Similar Documents

Publication Publication Date Title
JP2015205922A5 (enExample)
JP6561105B2 (ja) 過活動膀胱の治療のための医薬製剤
JP2014516080A5 (enExample)
JP2017019858A5 (enExample)
ES2623176T3 (es) Composición farmacéutica de memantina
JP2011519967A5 (enExample)
JP7787190B2 (ja) センタナファジン製剤ならびにその製造および使用方法
JP2016516698A5 (enExample)
RU2017141029A (ru) Фармацевтическая пероральная композиция изотретиноина для применения один раз в сутки
JP2016523250A5 (enExample)
TW201815383A (zh) 用於藥學用途之多層珠粒
HRP20161340T1 (hr) Formulacije darunavira
WO2012053785A3 (ko) 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
Pan et al. Novel compaction techniques with pellet-containing granules
HRP20141134T1 (hr) Kruta farmaceutska formulacija
JP6084355B2 (ja) アンブロキソール含有製剤粒子
JP2015120758A5 (enExample)
CN102552218A (zh) 一种盐酸美金刚胶囊缓释剂及其制备方法
JP5619970B2 (ja) 生理活性物質含有粒子の製造方法
WO2015085739A1 (zh) 一种多层固体药物剂型
JP2015086194A (ja) ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物
JP5934835B2 (ja) 腸溶性細粒及び医薬組成物
JPWO2020218518A5 (enExample)
CN104274387A (zh) 美托洛尔缓释组合物
JP2015503574A (ja) 4’−[(1,4’−ジメチル−2’−プロピル[2,6’−ビ−1h−ベンズイミダゾル]−1’−イル)メチル]−[1,1’−ビフェニル]−2−カルボン酸および6−クロロ−3,4−ジヒドロ−2h−1,2,4−ベンゾチアジアジン−7−スルホンアミド−1,1−ジオキシドから構成される薬学的組成物